Abbott Diagnostics Product Pipeline Analysis

SUMMARY

Abbott Diagnostics Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Abbott Diagnostics's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List Of Tables 8
1.2 List of Figures 9
2 Company Overview 10
2.1 Key Information 10
2.2 Industry Outlook -- In Vitro Diagnostics 10
3 Major Products and Services 11
3.1 Overview 11
4 Competitors 13
5 Key Employees 14
6 Locations And Subsidiaries 15
6.1 Head Office 15
6.2 Other Locations & Subsidiaries 15
7 Recent Developments 17
7.1 Product News 17
7.1.1 Jul 29, 2008: Novel Diagnostic Marker For Acute Kidney Injury Previewed At Abbott Laboratories-Sponsored Scientific Workshop 17
7.1.2 Apr 15, 2008: Innovative Diagnostic Instrument Introduced By Abbott For Low- To Mid-Volume Laboratory Market Segment Highly Anticipated ARCHITECT i1000SR Analyzer Enhances Workflow And Boosts Laboratory Productivity 17
7.1.3 Jan 18, 2008: Abbott Announces Approval Of First Fully Automated Blood Screening Test For HTLV-I/HTLV-II 18
7.1.4 Jan 17, 2008: Abbott RealTime PCR Test For Detection Of New Variant Strain Of Chlamydia Receives CE Mark Certification 18
7.1.5 Dec 03, 2007: Abbott Receives FDA Approval For Automated Hepatitis B Test For Use On Architecta Immunoassay Analyzers 18
7.1.6 Jul 16, 2007: Abbott Showcases Its ARCHITECT i4000SR At AACC Annual Meeting 19
7.1.7 Jul 16, 2007: Abbott Unveils ARCHITECT c4000 At The American Association Of Clinical Chemistry 19
7.1.8 Jul 16, 2007: Abbott Unveils ARCHITECT ci4100 At The American Association Of Clinical Chemistry 19
7.1.9 Jul 16, 2007: Abbott Unveils Newest Upcoming Members Of Architect Family Of Instruments 19
7.1.10 Jul 16, 2007: Abbott Unveils Newest Upcoming Members Of Architect Family Of Instruments 20
7.1.11 Jun 21, 2007: Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking In Europe 20
7.1.12 Jan 10, 2005: Company Licenses Homocysteine Patent To Abbott 21
7.2 Product Approvals 21
7.2.1 Jan 18, 2008: Abbott Announces Approval Of First Fully Automated Blood Screening Test For HTLV-I/HTLV-II 21
7.2.2 Jan 17, 2008: Abbott RealTime PCR Test For Detection Of New Variant Strain Of Chlamydia Receives CE Mark Certification 22
7.2.3 Dec 03, 2007: Abbott Receives FDA Approval For Automated Hepatitis B Test For Use On Architecta Immunoassay Analyzers 22
7.2.4 Jun 21, 2007: Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking In Europe 22
7.3 Clinical Trials 23
7.3.1 Jul 29, 2008: Novel Diagnostic Marker For Acute Kidney Injury Previewed At Abbott Laboratories-Sponsored Scientific Workshop 23
8 Abbott Diagnostics Pipeline Products 24
8.1 Abbott Diagnostics Product Pipeline Analysis 24
8.1.1 Abbott Diagnostics Pipeline Products By Equipment Type 24
8.1.2 Abbott Diagnostics Pipeline Products By Development Stage 27
8.1.3 Abbott Diagnostics Pipeline Products By Therapy Area 29
8.1.4 Abbott Diagnostics Pipeline Products By News Summary 30
8.2 ARCHITECT c4000 30
8.2.1 Product Description 31
8.2.2 Product Status 31
8.2.3 Product Milestone 31
8.3 ARCHITECT ci4100 32
8.3.1 Product Description 32
8.3.2 Product Status 32
8.3.3 Product Milestone 32
8.4 RealTime Chlamydia trachomatis 33
8.4.1 Product Description 33
8.4.2 Product Status 33
8.4.3 Product Milestone 33
8.5 NGAL assay 34
8.5.1 Product Description 34
8.5.2 Product Status 34
8.5.3 Product Milestone 34
8.6 Vitamin D assay 35
8.6.1 Product Description 35
8.6.2 Product Status 35
8.7 Copper assay 36
8.7.1 Product Description 36
8.7.2 Product Status 36
8.8 Cystatin C 36
8.8.1 Product Description 36
8.8.2 Product Status 37
8.9 D-Dimer Assay 37
8.9.1 Product Description 37
8.9.2 Product Status 37
8.10 Fructosamine assay 37
8.10.1 Product Description 37
8.10.2 Product Status 38
8.11 Homocysteine assay 38
8.11.1 Product Description 38
8.11.2 Product Status 38
8.11.3 Product Milestone 39
8.11.4 Product Patent Details 39
8.12 Pepsinogen I assay 40
8.12.1 Product Description 40
8.12.2 Product Status 40
8.13 Pepsinogen II assay 40
8.13.1 Product Description 40
8.13.2 Product Status 41
8.14 TIMP-1 assay 41
8.14.1 Product Description 41
8.14.2 Product Status 41
8.15 MPO assay 41
8.15.1 Product Description 41
8.15.2 Product Status 42
8.16 EDDP assay 42
8.16.1 Product Description 42
8.16.2 Product Status 42
8.17 Anti-HAV IgG assay 42
8.17.1 Product Description 43
8.17.2 Product Status 43
8.18 Lidocaine assay 43
8.18.1 Product Description 43
8.18.2 Product Status 43
8.19 Tg assay 43
8.19.1 Product Description 44
8.19.2 Product Status 44
8.20 Cyclosporine assay 44
8.20.1 Product Description 44
8.20.2 Product Status 44
8.21 Aeroset Creatinine (Enzymatic) assay 45
8.21.1 Product Description 45
8.21.2 Product Status 45
8.22 ARCHITECT c8000 Barbiturates-Serum assay 45
8.22.1 Product Description 45
8.22.2 Product Status 46
8.23 ARCHITECT c8000 Benzodiazepines-Serum assay 46
8.23.1 Product Description 46
8.23.2 Product Status 46
8.24 ARCHITECT c8000 Creatinine (Enzymatic) assay 47
8.24.1 Product Description 47
8.24.2 Product Status 47
8.25 ARCHITECT i2000SR AFP assay 47
8.25.1 Product Description 47
8.25.2 Product Status 48
8.26 ARCHITECT i2000SR C-Peptide assay 48
8.26.1 Product Description 48
8.26.2 Product Status 48
8.27 ARCHITECT i2000SR Cyclosporine assay 48
8.27.1 Product Description 49
8.27.2 Product Status 49
8.28 ARCHITECT i2000SR Phenobarbital assay 49
8.28.1 Product Description 49
8.28.2 Product Status 49
8.29 ARCHITECT i2000SR Phenytoin assay 50
8.29.1 Product Description 50
8.29.2 Product Status 50
8.30 ARCHITECT i2000 AFP assay 50
8.30.1 Product Description 50
8.30.2 Product Status 51
8.31 ARCHITECT i2000 C-Peptide assay 51
8.31.1 Product Description 51
8.31.2 Product Status 52
8.32 ARCHITECT i2000 Phenobarbital assay 52
8.32.1 Product Description 52
8.32.2 Product Status 53
8.33 ARCHITECT i2000 Phenytoin assay 53
8.33.1 Product Description 53
8.33.2 Product Status 54
8.34 ARCHITECT i2000 HIV Ag/Ab Combo assay 54
8.34.1 Product Description 54
8.34.2 Product Status 55
9 Appendix 56
9.1 Methodology 56
9.1.1 Coverage 56
9.1.2 Secondary Research 57
9.1.3 Primary Research 57
9.1.4 Expert Panel Validation 58
9.2 Contact Us 58
9.3 About Global Markets Direct 58
9.4 Disclaimer 58

1.1 List of Tables
Table 1: Abbott Diagnostics,Key Facts 10
Table 2: Abbott Diagnostics, Key Employees, 14
Table 3: Abbott Diagnostics, Other Locations 15
Table 4: Abbott Diagnostics Pipeline Products by Equipment Type 26
Table 5: Abbott Diagnostics Pipeline Products By Development Stage 28
Table 6: Abbott Diagnostics Pipeline Products By Therapy Area 29
Table 7: Abbott Diagnostics Pipeline Products By News Summaries 30

1.2 List of Figures
Figure 1: Abbott Diagnostics Pipeline Products By Equipment Type 24
Figure 2: Abbott Diagnostics Pipeline Products By Equipment Type 25
Figure 3: Abbott Diagnostics Pipeline Products By Development Stage 27
Figure 4: Abbott Diagnostics Pipeline Products By News Summary 30
Figure 5: Global Markets Direct Methodology 56